Clinigen and Cumberland collaborate in mutual market access deal
Cumberland Pharmaceuticals is a Nashville, Tennessee-based specialty pharma firm with a portfolio of products including acetylcysteine for the treatment of acetaminophen poisoning, and an ibuprofen injection to manage pain available in the US.
Clinigen, meanwhile, is a UK-based firm which markets its own portfolio of niche pharmaceuticals, on top of supplying commercial medicines for clinical trials.
In the accord announced today, both firms will be marketing, promoting and distributing each other’s portfolios in their home markets.
“A key strategic initiative this year has been to develop our Group's global distribution footprint,” said Clinigen’s CEO Peter George. “The US is a particular area of focus where we are looking to initiate a long term strategic partnership and Cumberland was a natural fit as a partner.
“Working together is a logical move for both companies as we will mutually benefit from each other's distribution expertise and capabilities in our respective regions,” he said, while Cumberland’s CEO AJ Kazimi added in a statement the deal “creates a new growth driver for both companies that builds on our strengths.”
Earlier this year, Clinigen was selected by AstraZeneca for its global access programme (GAP) to provide access for the investigational antibiotic CAZ-AVI to eligible patients outside the US and Canada.
